Menopause Protein Changes Linked to Dementia Risk, says Biermann Medizin

Blood protein concentrations change during the menopausal transition and link to future dementia risk, according to a study published in Nature Medicine and reported by Biermann Medizin. Researchers at the University of California, San Francisco identified 16 proteins that rise during midlife hormonal changes and correlate with impaired memory, reduced cognitive function, and higher Alzheimer’s risk decades later in older women.

Brain Protein Shifts During Midlife Hormonal Changes

Two thirds of Alzheimer’s patients are women, a disparity that average longer lifespans alone cannot explain. To investigate the underlying biological factors, researchers examined 80 women aged 40 to 59 using the STRAW+10 clinical tool, which combines symptoms and hormone levels to track exact points in the menopausal transition. Using a commercial blood test measuring over 100 brain health proteins, the team isolated 16 proteins whose concentrations shifted alongside hormonal fluctuations rather than chronological age. Inflammatory proteins increased when estradiol levels dropped, while Alzheimer-associated proteins rose alongside higher follicle-stimulating hormone values.

The team validated these molecular findings in dataset analyses covering more than 2,800 women from the UK Biobank. When analyzing older cohorts comprising nearly 12,000 women in their sixties and seventies from four previous studies, researchers observed that higher concentrations of those same proteins aligned with worse memory function. We are not assuming that menopause directly causes dementia, said Dr. Kaitlin Casaletto, associate professor at the UCSF Fein Memory and Aging Center and co-author of the study, as reported by Biermann Medizin. It is however possible that we can predict a woman’s dementia risk for decades later based on the concentration of these molecules during menopause.

Menopause Proteomics Score Correlates with Alzheimer's Risk

A higher menopause proteomics score connected to an estimated 15 percent greater risk for Alzheimer’s dementia in the analyzed older cohorts. Co-senior author Rowan Saloner, assistant professor at the UCSF Fein Memory and Aging Center, noted that the research identifies molecular changes in midlife women that shed light on later cognitive performance, establishing these molecules as important markers for both menopause and cognitive aging. The study also recorded that women reporting night sweats exhibited sharper increases in proinflammatorily active proteins during midlife, mirroring how earlier hot flashes linked to elevated inflammation markers in older age.

Researchers observed that a small sample of midlife men displayed molecular profiles closely resembling postmenopausal women, which suggests the menopausal transition triggers a compressed timeline of biological aging processes that unfold more gradually in men. We identify molecular changes in the blood of middle-aged women after menopause, which also provide information about cognitive performance in later life, Rowan Saloner explained, according to Biermann Medizin.

Predictive Blood Testing Aims for Midlife Interventions

The primary goal of the UCSF research team is developing a standardized blood test functioning as an early warning indicator for dementia risk, similar to how cholesterol checks measure heart disease vulnerabilities. Such a diagnostic tool would allow clinicians to identify individuals who could benefit from early medical interventions during midlife. Midlife is a crucial phase for both men and women in which we can set the course for whether the brain in later life is more resilient or more vulnerable to dementia, Dr. Kaitlin Casaletto stated, as reported by Biermann Medizin. For women, menopause could be a particularly effective time for interventions.